Roberta Turiello
@rturiello.bsky.social
🥼 Post-doctoral Researcher at the Telethon Institute of Genetics and Medicine, NA🇮🇹
Previously Postdoc at IEO, UKB, Bonn 🇩🇪
🔬Genomic and Experimental Medicine |Rare cancers | Rare genetic diseases
🛸 Spatial Biology enthusiast
📚 Bookworm
🇮🇹 Padula, SA
Previously Postdoc at IEO, UKB, Bonn 🇩🇪
🔬Genomic and Experimental Medicine |Rare cancers | Rare genetic diseases
🛸 Spatial Biology enthusiast
📚 Bookworm
🇮🇹 Padula, SA
June 24, 2025 at 2:51 PM
6
While the functional role of NKG7 continues to be explored, its consistent co-expression with cytotoxic signatures across diverse contexts makes it a powerful tool for profiling cytotoxic immune cells.
While the functional role of NKG7 continues to be explored, its consistent co-expression with cytotoxic signatures across diverse contexts makes it a powerful tool for profiling cytotoxic immune cells.
June 24, 2025 at 2:22 PM
6
While the functional role of NKG7 continues to be explored, its consistent co-expression with cytotoxic signatures across diverse contexts makes it a powerful tool for profiling cytotoxic immune cells.
While the functional role of NKG7 continues to be explored, its consistent co-expression with cytotoxic signatures across diverse contexts makes it a powerful tool for profiling cytotoxic immune cells.
5
These findings position NKG7 as a robust, versatile marker for cytotoxicity—relevant for both basic immunology and translational research in cancer and immune-mediated diseases.
These findings position NKG7 as a robust, versatile marker for cytotoxicity—relevant for both basic immunology and translational research in cancer and immune-mediated diseases.
June 24, 2025 at 2:22 PM
5
These findings position NKG7 as a robust, versatile marker for cytotoxicity—relevant for both basic immunology and translational research in cancer and immune-mediated diseases.
These findings position NKG7 as a robust, versatile marker for cytotoxicity—relevant for both basic immunology and translational research in cancer and immune-mediated diseases.
4
• Notably, NKG7 expression persists even in PRF1-negative populations, suggesting its utility in tracking alternative or noncanonical cytotoxic programs.
• We also showed that NKG7 is highly expressed in CD4-CTLs, an emerging effector subset in cancer immunity.
• Notably, NKG7 expression persists even in PRF1-negative populations, suggesting its utility in tracking alternative or noncanonical cytotoxic programs.
• We also showed that NKG7 is highly expressed in CD4-CTLs, an emerging effector subset in cancer immunity.
June 24, 2025 at 2:22 PM
4
• Notably, NKG7 expression persists even in PRF1-negative populations, suggesting its utility in tracking alternative or noncanonical cytotoxic programs.
• We also showed that NKG7 is highly expressed in CD4-CTLs, an emerging effector subset in cancer immunity.
• Notably, NKG7 expression persists even in PRF1-negative populations, suggesting its utility in tracking alternative or noncanonical cytotoxic programs.
• We also showed that NKG7 is highly expressed in CD4-CTLs, an emerging effector subset in cancer immunity.
3
What we found:
• NKG7 consistently marks cytotoxic immune cells — even in complex tissue environments like tumors.
• It outperforms traditional markers like GZMB and PRF1 in reliability and consistency.
What we found:
• NKG7 consistently marks cytotoxic immune cells — even in complex tissue environments like tumors.
• It outperforms traditional markers like GZMB and PRF1 in reliability and consistency.
June 24, 2025 at 2:21 PM
3
What we found:
• NKG7 consistently marks cytotoxic immune cells — even in complex tissue environments like tumors.
• It outperforms traditional markers like GZMB and PRF1 in reliability and consistency.
What we found:
• NKG7 consistently marks cytotoxic immune cells — even in complex tissue environments like tumors.
• It outperforms traditional markers like GZMB and PRF1 in reliability and consistency.
2
In our study, we performed a comprehensive profiling of cytotoxicity-associated transcripts across immune subsets and tissues.
In our study, we performed a comprehensive profiling of cytotoxicity-associated transcripts across immune subsets and tissues.
June 24, 2025 at 2:21 PM
2
In our study, we performed a comprehensive profiling of cytotoxicity-associated transcripts across immune subsets and tissues.
In our study, we performed a comprehensive profiling of cytotoxicity-associated transcripts across immune subsets and tissues.
1
Cytotoxicity is essential for immune defense against tumors and infections, typically assessed using markers such as granzyme B (GZMB) and perforin (PRF1). However, less is known about other cytotoxic components.
Cytotoxicity is essential for immune defense against tumors and infections, typically assessed using markers such as granzyme B (GZMB) and perforin (PRF1). However, less is known about other cytotoxic components.
June 24, 2025 at 2:20 PM
1
Cytotoxicity is essential for immune defense against tumors and infections, typically assessed using markers such as granzyme B (GZMB) and perforin (PRF1). However, less is known about other cytotoxic components.
Cytotoxicity is essential for immune defense against tumors and infections, typically assessed using markers such as granzyme B (GZMB) and perforin (PRF1). However, less is known about other cytotoxic components.
🔵 Tim Kempchen poster #91
🟡 Lukas Kiwitz poster #95
🟡 Lukas Kiwitz poster #95
December 12, 2024 at 3:07 PM
🔵 Tim Kempchen poster #91
🟡 Lukas Kiwitz poster #95
🟡 Lukas Kiwitz poster #95